On February 6, the FDA approved caplacizumab-yhdp (Cablivi), the first therapy specifically indicated for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. The drug is approved for use in combination with plasma exchange and immunosuppressive therapy.
On February 6, the FDA approved caplacizumab-yhdp (Cablivi), the first therapy specifically indicated for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. The drug is approved for use in combination with plasma exchange and immunosuppressive therapy.
Patients with aTTP, a rare, life-threatening autoimmune blood disorder, experience blood clots in small blood vessels throughout the body. These clots can block vessels and decrease or stop blood flow to organs, causing neurological problems, fever, abnormal kidney function, abdominal pain, and heart problems.
Episodes of aTTP typically occur suddenly and last for days or weeks, and up to 20% of patients die from aTTP epidoses, with most deaths occurring within 30 days of diagnosis.
While aTTP is typically treated with plasma exchange and immune suppressants, relapses occur in up to 60% of patients who have aTTP. Caplacizumab, which is administered at the start of plasma exchange, targets von Willebrand factor (vWF), a protein in the blood that is involved in hemostasis. The drug, which is one of a novel class of therapeutic proteins based on single-domain antibody fragments, is designed to inhibit the interaction between vWF and platelets.
"For those faced with this rare diagnosis, the treatment and care can be difficult, and the threat of recurrence is ever-present," said Spero R. Cataland, MD, professor of internal medicine in the division of hematology at the Wexner Medical Center at the Ohio State University, in a statement. "Cablivi provides new hope for adults in the [United States] suffering with aTTP and provides a much-needed treatment option to help effectively manage aTTP episodes."
Approval of caplacizumab was based on results of the HERCULES phase 3 clinical study in 145 adult patients with aTTP that evaluated the drug in combination with plasma exchange and immunosuppressive therapy versus placebo in combination with plasma exchange and immunosuppressive therapy.
In the study, patients who received the drug had a significantly shorter time to platelet count response versus the placebo group. Caplacizumab also showed a significant reduction on a composite end point of aTTP-related death, recurrence of aTTP, or a major thromboembolic event during the study versus plasma exchange and immunosuppression alone.
During the HERCULES study and the phase 2 TITAN study, the most frequently reported adverse events were bleeding from the nose, headache, and bleeding from the gums.
Sanofi, the maker of the drug, says that it expects the drug to launch in the late first quarter of 2019. The list price for the treatment of a single episode of aTTP will be $270,000, and Sanofi says that it will soon launch a patient support program and will provide eligible patients with financial assistance.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More